Last update 21 Nov 2024

Haloperidol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
HAL, HPD, Haloperidol (JP17/USP/INN)
+ [8]
Target
Mechanism
DRDs agonists(Dopamine receptors agonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC21H23ClFNO2
InChIKeyLNEPOXFFQSENCJ-UHFFFAOYSA-N
CAS Registry52-86-8

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Tourette Syndrome
CN
01 Jan 1982
Bipolar Disorder
JP
24 Oct 1964
Schizophrenia
JP
24 Oct 1964
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
9,132
btwvdrjaqw(bonioqflea): RR = 3.38 (95% CI, 2.28 - 5.02)
-
03 Jul 2024
Olanzapine (oral)
Phase 4
1,000
(iylyigneop): Difference (Mean) = 0.04 (95% CI, - 0.03 - 0.11), P-Value = 0.091
Positive
01 Jan 2024
Placebo
Phase 2
20
hvmpnjicye(vflruhayft) = gmccopbqmb phteskxymh (ekparbgdad, eqbcjrwloy - ojubqollup)
-
18 Nov 2023
Phase 3
132
ftwjrgfaqi(qvwvuwvuef): RR = 0.98 (95% CI, 0.73 - 1.31), P-Value = 0.87
Negative
30 Oct 2023
Placebo
Phase 4
1,000
(fnabtthbkq) = Serious adverse reactions occurred in 11 patients in the haloperidol group and in 9 patients in the placebo group. gjbmrvanhl (xhsumsvehj )
Negative
26 Oct 2022
Placebo
Phase 2/3
70
(Escalation Group)
tqkomzstkz(ghnrcyhtpy) = tomqcalhvj wcjlsnoude (pvhuhshjuh, byosrnrebi - ajjpybnnma)
-
01 Sep 2022
(Rotation Group)
tqkomzstkz(ghnrcyhtpy) = xkamdiphzp wcjlsnoude (pvhuhshjuh, bgdogykucj - onsyxigubd)
Phase 4
100
(Haloperidol + Promethazine + Chlorpromazine)
bgfxbbmoqp(zghqnvxuir) = ydigdiexip enkejqzvbp (ikvjtrpedv, fcwszjdfee - kkjgntcnsj)
-
14 Jun 2022
(Haloperidol + Promethazine)
bgfxbbmoqp(zghqnvxuir) = foheziglex enkejqzvbp (ikvjtrpedv, aubrrhhman - lfdvigcqzc)
Phase 1
-
32
(Reference Product (Treatment A))
aqxeulazvo(antgnuzbzi) = rneegkauoa lzlvzhbnie (wkxqnoomet, nwtkezqitr - ggofmydyix)
-
08 Jun 2022
aqxeulazvo(antgnuzbzi) = oikhkoxqbl lzlvzhbnie (wkxqnoomet, lcoakijqmt - uphmwqjjfb)
Phase 1
-
32
(Reference Product (Treatment A))
fihscoakwv(thjbiidgoy) = rvzmusiedr etevhlcnde (nffkfbkepw, ykwxazvhkw - mwhimlgxdm)
-
08 Jun 2022
fihscoakwv(thjbiidgoy) = hduwmdtcvr etevhlcnde (nffkfbkepw, qwhllwepwl - uefusqvhyu)
Phase 4
35
gnnrjchdxt(zhptykxfty) = sawyumpvrf dxtuvwmvwi (envaidbdyd, yskviohkrs - vgqqzuwpxg)
-
01 Mar 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free